Send to

Choose Destination
See comment in PubMed Commons below
Neurosci Lett. 2008 Oct 31;444(3):280-5. doi: 10.1016/j.neulet.2008.08.052. Epub 2008 Aug 22.

Structural requirements for the flavonoid fisetin in inhibiting fibril formation of amyloid beta protein.

Author information

  • 1Laboratory of Pharmacology, Faculty of Pharmacy and Research Institute of Pharmaceutical Sciences, Musashino University, 1-1-20 Shinmachi, Nishitokyo-shi, Tokyo 202-8585, Japan.


Fisetin (3,3',4',7-tetrahydroxyflavone) has been found to be neuroprotective, induce neuronal differentiation, enhance memory, and inhibit the aggregation of the amyloid beta protein (Abeta) that may cause the progressive neuronal loss in Alzheimer's disease. The diverse collection of biological activities of this compound may lead to a new type of therapeutic drug for Alzheimer's disease. As the first step to design even more effective drugs based upon the structure of fisetin, the present study investigated the structural requirements for the anti-amyloidogenic activity of fisetin by comparing the effects of several structurally related flavonoids on Abeta fibril formation in vitro. Abeta1-42 (20muM) and the flavonoids were incubated for 0-48h at 37 degrees C, and fibril formation was quantitatively determined by the thioflavin T fluorescence assay. Among ten flavonoids tested, fisetin, 3',4',7-trihydroxylflavone, 3,3',4'-trihydroxyflavone, luteolin, quercetin and myricetin inhibited Abeta fibril formation. On the other hand, 3,3',7-trihydroxyflavone, 5-deoxykaempferol, chrysin and kaempferol enhanced Abeta fibril formation. These results suggest that the 3',4'-dihydroxyl group, but not the 3- or 7-hydroxyl group, is essential for the inhibitory effect of fisetin on Abeta fibril formation.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center